Muthusamy Shanmugam - 19 Jan 2024 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Role
HEAD OF R&D, COO-NOVITIUM OPS, Director
Signature
/s/ Muthusamy Shanmugam, by attorney-in-fact Meredith W. Cook
Issuer symbol
ANIP
Transactions as of
19 Jan 2024
Transactions value $
-$1,416,466
Form type
4
Filing time
23 Jan 2024, 17:32:18 UTC
Previous filing
18 Jan 2024
Next filing
16 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIP Common Stock Sale -$251K -4.52K -0.5% $55.57 903K 19 Jan 2024 Held by Esjay LLC F1, F2, F3
transaction ANIP Common Stock Sale -$318K -5.69K -0.63% $55.95 898K 22 Jan 2024 Held by Esjay LLC F1, F3, F4
transaction ANIP Common Stock Sale -$847K -15K -1.67% $56.44 883K 23 Jan 2024 Held by Esjay LLC F1, F3, F5
holding ANIP Common Stock 47.4K 19 Jan 2024 Direct
holding ANIP Common Stock 5K 19 Jan 2024 Held by SS Pharma LLC F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 21, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $55.03 to $56.00, inclusive.
F3 The reporting person holds voting and dispositive power over the shares held by Esjay LLC.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $55.63 to $56.21, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $56.00 to $57.11, inclusive.
F6 The Reporting Person holds voting and dispositive power over the shares held by SS Pharma LLC.